190 related articles for article (PubMed ID: 18264138)
1. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes.
Cai Z; Zhang G; Zhou Z; Bembas K; Drebin JA; Greene MI; Zhang H
Oncogene; 2008 Jun; 27(27):3870-4. PubMed ID: 18264138
[TBL] [Abstract][Full Text] [Related]
2. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies.
Zhang H; Wang Q; Montone KT; Peavey JE; Drebin JA; Greene MI; Murali R
Exp Mol Pathol; 1999 Sep; 67(1):15-25. PubMed ID: 10493889
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21.
Zhou H; Zha Z; Liu Y; Zhang H; Zhu J; Hu S; Shen G; Cheng L; Niu L; Greene MI; Teng M; Liu J
J Biol Chem; 2011 Sep; 286(36):31676-83. PubMed ID: 21680730
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.
Doyle HA; Koski RA; Bonafé N; Bruck RA; Tagliatela SM; Gee RJ; Mamula MJ
Cancer Immunol Immunother; 2018 Oct; 67(10):1559-1569. PubMed ID: 30056598
[TBL] [Abstract][Full Text] [Related]
6. AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu.
Masuda K; Richter M; Song X; Berezov A; Masuda K; Murali R; Greene MI; Zhang H
Oncogene; 2006 Dec; 25(59):7740-6. PubMed ID: 16785990
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
8. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.
Franklin MC; Carey KD; Vajdos FF; Leahy DJ; de Vos AM; Sliwkowski MX
Cancer Cell; 2004 Apr; 5(4):317-28. PubMed ID: 15093539
[TBL] [Abstract][Full Text] [Related]
9. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.
Adams CW; Allison DE; Flagella K; Presta L; Clarke J; Dybdal N; McKeever K; Sliwkowski MX
Cancer Immunol Immunother; 2006 Jun; 55(6):717-27. PubMed ID: 16151804
[TBL] [Abstract][Full Text] [Related]
10. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
Takai N; Jain A; Kawamata N; Popoviciu LM; Said JW; Whittaker S; Miyakawa I; Agus DB; Koeffler HP
Cancer; 2005 Dec; 104(12):2701-8. PubMed ID: 16265675
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
12. Antibody therapy for breast cancer.
Willems A; Gauger K; Henrichs C; Harbeck N
Anticancer Res; 2005; 25(3A):1483-9. PubMed ID: 16033049
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
J Clin Oncol; 1996 Mar; 14(3):737-44. PubMed ID: 8622019
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
[TBL] [Abstract][Full Text] [Related]
15. HER2 targeted therapy in breast cancer...beyond Herceptin.
Pal SK; Pegram M
Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.
Yamamoto N; Yamada Y; Fujiwara Y; Yamada K; Fujisaka Y; Shimizu T; Tamura T
Jpn J Clin Oncol; 2009 Apr; 39(4):260-6. PubMed ID: 19261664
[TBL] [Abstract][Full Text] [Related]
17. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
[TBL] [Abstract][Full Text] [Related]
18. [Molecular protocol for HER2/neu analysis in breast carcinoma].
Artufel MV; Valero AC; Lladó RR; Sagalés NE; Llorca MC; Carazo AM; Cardó CC; Torrus XP
Clin Transl Oncol; 2005 Dec; 7(11):504-11. PubMed ID: 16373062
[TBL] [Abstract][Full Text] [Related]
19. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.
Nahta R; Hung MC; Esteva FJ
Cancer Res; 2004 Apr; 64(7):2343-6. PubMed ID: 15059883
[TBL] [Abstract][Full Text] [Related]
20. [Immunocytochemical visualization of P185(HER2) receptor by antibody fused with dibarnase and conjugate of barstar with colloidal gold].
Ivanova IuL; Edelweiss EF; Leonova OG; Balandin TG; Popenko VI; Deev SM
Mol Biol (Mosk); 2013; 47(5):806-17. PubMed ID: 25509353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
